Pfiz­er Foun­da­tion of­fers $2M in grants to NGOs tack­ling an­timi­cro­bial re­sis­tance; Bio­gen, In­vi­tae join forces to de­vel­op faster SMA di­ag­nos­tic

→ Most of Big Phar­ma has left the build­ing when it comes to an­timi­cro­bial drug de­vel­op­ment, and small com­pa­nies with new­ly ap­proved an­tibi­otics are strug­gling to stay afloat. Mean­while, the foun­da­tion arm of Pfiz­er $PFE is of­fer­ing its sup­port, in the form of grants for NGO and so­cial en­ter­pris­es that are work­ing on ad­dress­ing this ma­jor health chal­lenge: an­timi­cro­bial re­sis­tance. Re­cip­i­ents of the one-year Glob­al Health In­no­va­tion Grants in­clude part­ners in 12 low- and mid­dle-in­come coun­tries who will each re­ceive $100,000. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER